Technical Data
Prostaglandin D Synthase, Lipocalin form (PGD Synthase, L-PGDS)
Prostaglandin D synthase (PGDS) catalyzes the isomerization of PGH2 to produce PGD2. PGD2 induces sleep, regulates nociception, inhibits platelet aggregation, and acts as an allergic mediator. Two distinct types of PGDS have been identified, namely the lipocalin type enzyme (beta-trace) and the hematopoietic enzyme (1,2). Lipocalin-type PGDS (L-PGDS) is localized in the central nervous system, genital organs of various mammals, and the human heart (1,3-5). Patients with chronic renal failure and hypertension exhibit elevated amounts of L-PGDS in serum and urine (6). The L-PGDS has been identified as beta-trace, which is a major protein in the human cerebrospinal fluid (2,7). Human L-PGDS is a 190 amino acid protein and can be detected at 24-26kD by immunoblotting.

Suitable for use in Immunohistochemistry and Western Blot. Other applications not tested.

Recommended Dilutions:
Immunohistochemistry: 1:2000
Western Blot: 1:1000 Incubate for 1 hour at RT. Overnight incubations at 4C with greater dilutions have also produced optimal results.
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at -20C. Stable for 12 months at -20C. Reconstitute with sterile ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
PabIgGAffinity Purified
100ul-20CBlue IceMouseRabbit
~1mg/ml (after reconstitution)
Recombinant mouse lipocalin prostaglandin D synthase (L-PGDS).
Purified by Protein A affinity chromatography.
Supplied as a lyophilized powder. Reconstitute with 100ul sterile ddH2O.
Recognizes mouse L-PGDS. Species Crossreactivity: human
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Urade, Y., Watanabe, K., and Hayaishi, O. J. Lipid Mediators Cell Signalling 12, 257-273 (1995). 2. Toh, H., Kubodera, H., Nakajima, N., et al. Protein Engineering 9, 1067-1082 (1996). 3. Tokugawa, Y., Kunishige, I., Kuboto, Y., et al. Biol. Reprod. 58, 600-607 (1998). 4. Melegos, D.N., Diamandis, E.P., Oda, H., et al. Clin. Chem. 42, 1984-1991 (1996). 5. Kanaoka, Y., Fujimori, K., Kikuno, R., et al. Eur. J. Biochem. 267, 3315-3322 (2000). 6. Hirawa, N., Uehara, Y., Yamakado, M., et al. Hypertension 39(part 2), 449-454 (2002). 7. Zahn, M., Mder, A., Schmidt, B., et al. Neurosci. Lett. 154, 93-95 (1993).